Medical Device Registration in Russia. Challenges and Issues

Webinar: Medical Device Registration in Russia. Challenges and Issues

The purpose of this webinar is to show the differences and specifics of regulations and law processes that can cause challenges in medical device registration in Russia.


You will learn about:

1. The specificity of national classification of medical devices

  • What is a Medical Device and what is not a Medical Device?
  • Why some medical products are medical devices in the EU but not considered as medical devices in Russia?

2. Key issues with the registration of complex and multi-component medical devices

  • Complex IVD Systems
  • Multi-component MD (Construction Kit)
  • MD with measuring function
  • Dermal Fillers with Lidocaine
  • Drug-Device combinations

3. National approach to Medical Software (SaMD)


Expanding into the Russian market?

Make use of our experts to guide you from the start to a full market access. Explore your options in a chat with one of our experts.

Who should attend? Professionals from Medical Device companies working within:

  • Regulatory
  • R&D
  • QA/QC
  • Compliance
  • Product Development
  • Manufacturing

Duration: 45 min.

Speaker: Regulatory Affairs Project Manager, Mikhail Vinogradov, LLM, who will discuss the key challenges and issues arising from the complex system of Medical Device registration in Russia.

Mikhail Vinogradov, LLM

Mikhail Vinogradov, LLM

Regulatory Affairs Project Manager

Other content that might interest you:

Download – ABO Whitepaper

Download – ABO Whitepaper

Whitepaper Regulatory Affairs Outsourcing Affiliate-Based Outsourcing for Regulatory Affairs acts as an addition or replacement of your in-house local regulatory capabilities. However, it frequently falls short of meeting the requirements for effective organization,...

read more

Recent Insights

Learn from Biomapas' experts and let us know what you'd like to hear about!

Challenges in early phase oncology trials
Clinical Trials Regulation
Challenges in early phase oncology trials